^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Published date:
05/05/2023
Excerpt:
...phase 3 trial was done at 52 centres across China and included patients...EGFR-mutated non-squamous NSCLC...Patients were randomly assigned (1:1:1), using an interactive web response system, to receive sintilimab (200 mg) plus IBI305 (15 mg/kg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2), sintilimab plus chemotherapy, or chemotherapy alone on day 1 of each 3-week cycle for four cycles, followed by maintenance therapy of sintilimab, IBI305, and pemetrexed....Sintilimab plus chemotherapy significantly improved progression-free survival compared with chemotherapy alone (median 5·5 months [95% CI 4·5–6·1] vs 4·3 months [4·1–5·3]; hazard ratio [HR] 0·72 [95% CI 0·55–0·94]; two-sided p=0·016).
Secondary therapy:
cisplatin + pemetrexed
DOI:
https://doi.org/10.1016/S2213-2600(23)00135-2
Trial ID:
Source:
Title:
A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Excerpt:
...Patients without activating EGFR mutation; 8....
Trial ID:
Source:
Title:
A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.
Excerpt:
...Patients without activating EGFR mutation; 8....
Trial ID:
More C2 evidence
Source:
Title:
A Multicenter, Single Arm Study to Determine the Efficacy of Cyberknife in Combination With Cindilizumab Synchronous Pemetrexed Plus Platinum Chemotherapy for the First-Line Treatment in Patients With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Excerpt:
......
Trial ID:
